Fig. 1
From: Epigenetic silencing of JAM3 promotes esophageal cancer development by activating Wnt signaling
The expression and methylation status of JAM3 in esophageal cancer. The association of JAM3 expression and methylation around TSS site. Scatter plots show reduced JAM3 expression is associated with methylation status of cg03637878, cg24625128 and cg04913256. b Semiquantitative RT-PCR shows the expression of JAM3 in EC cells. KYSE30, KYSE70, KYSE150, KYSE410, KYSE450, KYSE510, KYSE520, TE1, TE13, YES2 and BIC1 are EC cells. 5-aza: 5-aza-2′-deoxycytidine; GAPDH: internal control of RT-PCR; H2O: double distilled water; (−): absence of 5-aza; (+): presence of 5-aza. c MSP results of JAM3 in EC cells. U: unmethylated alleles; M: methylated alleles; IVD: in vitro methylated DNA, serves as methylation control; NL: normal lymphocytes DNA, serves as unmethylation control; and H2O: double distilled water. d BSSQ results of JAM3 in KYSE30, KYSE410, YES2 and KYSE450 cells. The size of unmethylated MSP products was 137 bp, and bisulfite sequencing was focused on a 271 bp region around the JAM3 transcription start site (− 191 to + 41 bp). Filled circles: methylated CpG sites; open circles: unmethylated CpG sites; and TSS: transcription start site